Gene Therapy for Sickle Cell Disease: A Complete Guide

Sickle cell disease (SCD) is a hereditary blood disease that persists for life. Millions of people suffer from this disease in many parts of the world, especially among people of different ethnic backgrounds, that consist of Africans, Asians and people of Mediterranean descent.

For a long time, the treatment of sickle cell disease relied mainly on addressing its common symptoms. This process proved to be effective for people, although it still requires adherence to treatment.

According to a study," SCD affects roughly 8 million people worldwide, with about 7.7 million cases documented globally."

Genetic engineering has proved capable of changing the situation once and for all through gene-therapeutic methods adapted to this condition. Because the gene responsible for sickle cell disease has been identified, gene therapy offers good prospects for addressing problems affecting patients with sickle cell disease.

The blog will provide useful information on gene therapy, its principles of operation, its efficacy in treating sickle cell disease, and its costs and availability.

Brief introduction to Sickle Cell Disease

The disease is linked to abnormal development of the HBB gene, which causes sickle cell disease. Unlike normal hemoglobin, the patientâ€™s body produces hemoglobin S (HbS), which under some circumstances leads to the red blood cells becoming deformed into stiff sickle shapes. These sickle cells can deprive the blood of the necessary oxygen by blocking the blood vessels

As a consequence of the deformity of the blood cells, a patient may suffer from the following illnesses:

Painful sickle cell crisis
Chronic anemia
Frequent infections
Stroke
Acute chest syndrome
Damage to different organs (heart, lungs, kidneys, and liver)
Stunted growth of sick children

Traditional therapies cure the complications of the disease but do not cure this genetic condition

What is Gene Therapy?

Gene therapy is a modern approach to curing disease by altering or repairing the gene that causes it. In sickle cell disease, the procedure involves collecting the patient's bone marrow stem cells and correcting the mutation in the laboratory. After chemotherapy, the corrected stem cells are returned to the patient.

Gene therapy marks a departure from lifelong disease management and opens possibilities for more effective treatment.

How is Gene Therapy Applied to Treat Sickle Cell Disease?

Various forms of gene therapy exist, but they share similar steps.

Step 1: Obtaining Stem Cells

First, the patients have their hematopoietic stem cells obtained from either the blood or bone marrow.

Step 2: The Modification Stage

Then, after the stem cells have been harvested or collected in the laboratory, they undergo processes to modify the defective HBB gene. This can be done by:

Making the necessary adjustments to the impaired HBB gene,
Introducing a new working copy of the HBB gene, or
Activating the gene responsible for fetal hemoglobin (HbF), which helps to prevent sickling.

These recent CRISPR technologies have made everything easy.

Step 3: Conditioning Chemotherapy

Before receiving the corrected stem cells, the patient undergoes chemotherapy.

Step 4: Infusion of Stem Cells

Then, after correcting the stem cells, they are returned to the body, just as in a stem-cell transplant.

Step 5: Fresh Healthy Blood Cells Creation

Consequently, the corrected stem cells begin producing red blood cells for several months. These cells can have either normal or fetal hemoglobin.

Can Gene Therapy Treat Sickle Cell Disease?

Yes, gene therapy can effectively treat sickle cell disease by modifying a patient's stem cells to produce healthy, non-sickling hemoglobin. It is a method in which specific genetic alterations are used to treat severe illness. Gene therapy was shown to be effective in clinical trials and in practice. The results from the patients treated with gene therapy showed:

Absence of painful sickle crises.
Freedom from regular blood transfusions.
Increased hemoglobin levels.
Better quality of life.
Fewer hospitalisations.
Increased physical activity in everyday life.

For many patients, gene therapy can be considered a cure because it can reduce symptoms or even eliminate them. Nevertheless, patients are monitored for long-term outcomes after treatment.

Who is Suitable for Gene Therapy?

Gene therapy is not suitable for every patient with sickle cell disease. Gene therapy is considered to be applicable for those patients who have:

Severe sickle cell disease with frequent crises
Good functioning of lungs, heart, liver, and kidneys
Good tolerance of chemotherapy
No uncontrolled infections
Evaluation at a specialised centre

The gene therapy method can be used on both children and adults.

Feature	Gene Therapy	Bone Marrow Transplant
Stem Cell Source	Patient's own stem cells	Stem cells from a matched donor
Need for a Donor	No	Yes
Risk of Graft-versus-Host Disease (GVHD)	Very low	Present
Best Suited For	Patients without a matched donor or those eligible for advanced gene-based treatment	Patients with a well-matched donor, especially younger individuals
Availability	Limited to specialised centres in select countries	Widely available at established transplant centres

The development of bone marrow transplantation has provided the best treatment for patients with a compatible donor, especially if they are young. In contrast, gene-based treatment is possible for patients without a matching donor or for those who would like to avoid complications which may occur during the transplant.

The choice of the best treatment method should be made based on the patient's general condition, age, availability of a donor, and consultation with a highly qualified hematologist.

At present, gene therapy for sickle cell disease is performed only in certain countries and institutions with genetic expertise. The countries where gene therapy or advanced gene therapy has been approved are as follows:

US
UK
Germany
France
Italy
Spain
Saudi Arabia (a few specialised centres)

Other countries where studies are ongoing or where there are advanced gene therapy programs. As the number of hospitals setting up new gene therapy centres rises, the accessibility of gene therapy is increasing in other countries as well.

The gene therapy patients need to consult specialised doctors or hospitals when they want to undergo treatment.

What are the risks of Gene Therapy?

Although gene therapy has a number of advantages, it is also a complex clinical procedure.

The risks of gene therapy may be related to:

Side effects caused by the chemotherapy
Hypoplastic crisis
Higher chance of getting infected in the course of recovery
Impairment of fertility connected with chemotherapy

This is why the technology has not been fully adopted yet: it is becoming more practical.

Although the upfront cost is substantial, researchers suggest that successful gene therapy may reduce lifetime healthcare expenses by decreasing hospital admissions, transfusions, medications, and complications.

How is recovery from gene therapy different from other therapies?

After chemotherapy and stem cell infusion, patients usually remain in the hospital for a few weeks while new stem cells start forming healthy blood cells.

During recovery, patients require:

Regular blood tests
Infection prevention measures
Follow-up imaging and assessments
Nutritional support
Close monitoring by hematologists

Aspect

Recovery After Gene Therapy

Recovery After Other Therapies (Chemotherapy, Blood Transfusions, Hydroxyurea, etc.)

Purpose

Aims to correct or modify the disease's underlying genetic cause.

Primarily manages symptoms, reduces complications, or controls disease progression.

Hospital Stay

Usually requires a longer hospital stay, especially if combined with stem cell transplantation.

Often involves shorter hospital visits or outpatient treatment, depending on the therapy.

Recovery Duration

Recovery may take several weeks to a few months as the body heals and new blood cells develop.

Recovery is generally quicker after each treatment session but requires ongoing treatment over time.

Monitoring

Close monitoring is needed to assess blood counts, immune recovery, and potential side effects.

Regular follow-up is required to monitor treatment response and adjust medications if needed.

Risk of Infection

Higher risk initially due to temporary immune suppression, requiring strict infection prevention.

Risk varies by treatment but is generally lower than after gene therapy or transplant.

Long-Term Outcome

May provide long-lasting benefits and reduce or eliminate the need for ongoing disease management in eligible patients.

Long-term treatment is often required to manage symptoms and prevent complications.

Follow-Up Care

Long-term follow-up is essential for monitoring treatment success and detecting delayed side effects.

Regular follow-up continues to assess disease control and adjust therapy as needed.

The Future of Gene Therapy for Sickle Cell Disease

Gene therapy has been hailed as one of the biggest discoveries in the treatment of genetic blood disorders. Scientists have been busy researching how to enhance its safety and effectiveness, make the treatment affordable, and reach patients worldwide.

Advancements in gene-editing techniques may eliminate the need for intensive chemotherapy and simplify treatment. With further technological developments, gene therapy has the potential to transform sickle cell disease from a chronic disease into a curable one.

Conclusion

Gene therapy has led to a new era in the treatment of sickle cell disease, as it cures the disease rather than merely treating its symptoms. The treatment is available to patients who meet the eligibility criteria.

Gene therapy has opened a new chapter in the treatment of sickle cell disease by targeting the genetic cause rather than simply managing symptoms. For eligible patients, it offers the possibility of long-term freedom from painful crises, fewer complications, and a dramatically improved quality of life.

While bone marrow transplantation remains an important curative option, gene therapy provides hope for patients who lack a suitable donor and represents a major step forward in precision medicine. Although challenges such as high cost and limited availability remain, continued research and the expansion of treatment programs are making this revolutionary therapy increasingly accessible.

Anyone considering gene therapy should consult a hematologist or a specialised treatment centre to determine eligibility, understand potential benefits and risks, and explore the most appropriate treatment options based on their individual medical needs.

Reference

Frequently Asked Questions

Gene therapy offers people the possibility of receiving a permanent cure for sickle cell disease because it acts on the root cause or the genetic defect that leads to the disease itself. Initial results were positive, but further evaluation and follow-up will be conducted to ascertain the efficacy and safety of the gene therapy method.

Gene therapy should be considered for people who suffer from sickle cell disease in its severest forms. When assessing the feasibility of using gene therapy for sickle cell disease, factors such as a patient's age, overall health, and the extent of essential organ function should be considered.

People are hospitalised for several weeks after the gene therapy. During this time, their stem cells will begin producing the necessary healthy blood cells. People usually recover fully in several months.

There are advantages and disadvantages to both methods. While gene therapy uses the person's own stem cells, which eliminates the risk of graft-versus-host disease (GVHD), a bone marrow transplant requires a matched donor. One method may be preferred over the other depending on the patient's condition and should be determined by a doctor.